Triazine derivatives and their use in the treatment of cancer
Patent Information
- Authority / Receiving Office
- DK · DK
- Patent Type
- Patents
- Current Assignee / Owner
- F HOFFMANN LA ROCHE & CO AG
- Filing Date
- 2022-06-02
- Publication Date
- 2026-06-29
AI Technical Summary
Current treatments for NLRP3-related diseases, such as CAPS, type 2 diabetes, and atherosclerosis, lack compounds with improved pharmacological and physiological properties and offer limited potency and specificity in inhibiting the NLRP3 inflammasome.
Development of novel triazine derivatives that form a 4-6 membered heterocycle or 3-6 membered cycloalkyl ring systems, optionally substituted with halo or alkyl groups, to inhibit NLRP3 activity, providing pharmaceutically acceptable salts and various synthetic methods.
The triazine derivatives effectively inhibit NLRP3, reducing inflammation and associated cytokine release, offering potential therapeutic benefits for a range of inflammatory and autoimmune diseases, including CAPS, type 2 diabetes, and atherosclerosis.